Leo Gordon

Jun 17, 2024 | law.com | Daniel Garrie |Michael Mann |Leo Gordon

Cybersecurity is becoming more important for the legal industry as more and more lawsuits involve large volumes of sensitive data. This is particularly true for multidistrict litigations (MDLs), which have become increasingly common in recent years. It is estimated that there are approximately 457,000 civil actions pending on MDL dockets, which represents approximately 67% of all pending civil litigation, throughout the United States, as of Dec.

Jun 13, 2024 | uft.org | Leo Gordon

Career and technical education may be the most dynamic sector of New York City public schools as educators race to keep pace with changing workforce needs. Industry partnerships, which are a crucial piece, are reshaping curricula and revolutionizing how we fund CTE programs in the city and throughout the nation. A prime example of this innovative approach is the recent partnership among the UFT, Micron Technology and the American Federation of Teachers, our parent union.

Feb 2, 2024 | law.com | Daniel Garrie |Leo Gordon |Andrew Denney

The digital age has significantly transformed the legal landscape, particularly in the realm of discovery. Electronic discovery (e-discovery) has emerged as a critical part of modern litigation, regarding the identification, collection, and production of electronically stored information (ESI). However, e-discovery processes can be complex, given the sheer volume and diversity of digital data, combined with the technical intricacies of data management and retrieval.

Dec 10, 2023 | brnw.ch | Michael Wang |Tanya Siddiqi |Leo Gordon |Matthew A Lunning

Your PrivacyASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us. Because we respect your right to privacy, you can choose not to allow some or all types of cookies.

Dec 10, 2023 | ascopubs.org | Michael Wang |Tanya Siddiqi |Leo Gordon |Manali K. Kamdar

Patients with relapsed/refractory MCL after ≥2 lines of prior therapy, including Bruton tyrosine kinase inhibitor (BTKi), alkylating agent, and CD20-targeted agent, received lisocabtagene maraleucel (liso-cel) at a target dose level of 50×10 6 (DL1) or 100×10 6 (DL2) CAR + T cells. Primary endpoints were adverse events, dose-limiting toxicities, and objective response rate (ORR) by independent review committee per Lugano criteria. Of 104 leukapheresed patients, liso-cel was infused into 88.